Business Wire

CO-OPTIV-SECURITY

30.5.2019 17:07:07 CEST | Business Wire | Press release

Share
Optiv Security Recognized with Second-Highest Score in Current Offering Category for Cybersecurity Incident Response Services in Independent Analyst Report

Optiv Security, a global cybersecurity integrator delivering end-to-end cybersecurity solutions, has been recognized with the second highest score in the current offering category for cybersecurity incident response services by Forrester Research. The Forrester WaveTM : Cybersecurity Incident Response Services, Q1 2019 identifies Optiv as having received the highest possible score for the criteria of incident preparation, post-incident reporting and support, and average hours per response.

The report cites that “Optiv … has an excellent current offering,” noting that “it has a well-stated engagement model, and its postmortem deliverables include remediation road maps to help clients avoid repeat occurrences, and its client references were positive across the board.” The report also states that “Optiv would be a good choice from incident preparation through remediation.”

“Today’s business decision makers are faced with driving technology, product, and business growth, while being simultaneously tasked with maintaining cyber resilient programs that are ready to react, respond to, and recover from adverse events,” said Bill Young, Optiv’s vice president and general manager of advisory threat management. “Achieving cyber resiliency requires a strategy that leverages security best practices, including proactive incident management planning, programmatic penetration testing, effective detection and response capabilities, and real-time tailored threat intelligence. By addressing enterprise cybersecurity needs from the perspective of the enemy, organizations can create more successful cyber resilient programs that are built on factual-based offensive security testing.”

Young continued, “Optiv is in a unique position in the industry to provide clients with unmatched insight, depth and breadth of services, as well as a bench that extends throughout the complete ‘plan, build, run’ cybersecurity lifecycle. We are focused on enabling our clients to move from putting out fires to preventing threat actor actions and enabling their businesses. We do this by helping organizations create, prepare, and execute incident response strategies that are honed and practiced as their organizations change, providing skilled and experienced resources to augment internal staff, and delivering supporting services, such as threat hunting and forensics capabilities that help reduce breach levels and data loss. We believe receiving the second highest score in the current offering category from Forrester validates our unique approach and the positive impact we have on our clients’ operations.”

Optiv’s enterprise incident management services help organizations reduce the likelihood of attacks or incidents, secure their environments against threats, and recover from incidents while minimizing disruption. Optiv’s full suite of EIM services can be purchased in structures aligned to the clients’ business model, thereby enabling organizations to:

  • Prepare – identify gaps in incident management strategy, hunt for and detect unknown threats within their infrastructure, document key personnel and escalation steps, validate and test response efforts for incidents and identify next steps to become more resilient.
  • Respond During and Post Incident – uncover attackers’ actions, detail the scope of a compromise, identify steps to remove active threats found in their environments, limit data loss, and improve security controls.
  • Maintain – ensure they are in a continual state of readiness for unexpected attacks or incidents with Optiv experts who are on-call and available 24x7x365. Optiv’s security and malware professionals examine clients’ systems for indicators of compromise, conduct analysis informed by a vast proprietary knowledge store of malicious code, signatures and attacks, and provide ongoing expertise.

Please visit Optiv’s website to learn more about Optiv’s incident management services .

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog

About Optiv Security
Optiv is a global cybersecurity solutions integrator – a “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organizations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .

Contact:

Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye